{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:48:42Z","timestamp":1791319722695,"version":"4.3.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Asociaci\u00f3n Espa\u00f1ola de cirujanos"},{"DOI":"10.13039\/501100019722","name":"Cardiolinc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Seroma after breast cancer surgery is a frequent entity; therefore, different products have been described in literature with the aim to reduce it. The most studied ones have been the sealants products, being tested with aspirative drains. Symptomatic seroma represents the 19% after axillary lymphadenectomy without drains. The aim of this study is to analyze the effect of a sealant in the seroma control after axillary lymphadenectomy without drains and identify the risk factors related to symptomatic seroma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective, multicenter, international, and randomized clinical trial. Patients undergoing conservative surgery and axillary lymphadenectomy for breast cancer will be randomized to control group (lymphadenectomy without sealant) or interventional group (lymphadenectomy with sealant Glubran 2\u00ae). In any of the study groups, drains are placed. Patients who received neoadjuvant treatment are included. Measurements of the study outcomes will take place at baseline; at 7, 14, and 30\u00a0days post-surgery; and at 6\u201312\u00a0months. The primary outcome is symptomatic seroma. Secondary outcomes are seroma volume, morbidity, quality of life, and lymphedema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Several studies compare the use of sealant products in axillary lymphadenectomy but generally with drains. We would like to demonstrate that patients who underwent axillary lymphadenectomy could benefit from an axillary sealant without drains and reduce axillary discomfort while maintaining a good quality of life. Assessing the relationship between axillary volume, symptoms, and related risk factors can be of great help in the control of seroma in patients who received breast cancer surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT05280353. Registration date 02 August 2022.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07840-w","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T10:02:59Z","timestamp":1708596179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Seroma control in axillary lymphadenectomy with Glubran 2\u00ae without drain. Multicenter, prospective, randomized, clinical trial. GALA-ND study (Glubran, Axillary Lymphadenectomy, Ambulatory, No Drain)"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9558-0041","authenticated-orcid":false,"given":"Sandra","family":"L\u00f3pez Gordo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Ruiz-Edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Fern\u00e1ndez-Planas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Viscaya-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Serra-Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Breast Cancer Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Buqueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Recaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Guerrero-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Blay-Aulina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Aparicio-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cusin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Clos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immaculada","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Cort\u00e9s Prados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Espinoza Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vallejo-Barnosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Espinoza-Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Carrasquer-Puyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila Giselle","family":"Holub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Cases Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garcia de Castro R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Herrador Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garcia de Castro Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Lourdes","family":"Gonzalez Duaigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"7840_CR1","unstructured":"SEOM. Las cifras del c\u00e1ncer en Espa\u00f1a 2021 2021. Available from: https:\/\/seom.org\/images\/Cifras_del_cancer_en_Espnaha_2021.pdf."},{"issue":"10","key":"7840_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326.","journal-title":"JAMA"},{"issue":"10","key":"7840_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ejso.2011.04.012","volume":"37","author":"AJ van Bemmel","year":"2011","unstructured":"van Bemmel AJ, van de Velde CJ, Schmitz RF, Liefers GJ. Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol. 2011;37(10):829\u201335.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"7840_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4048\/jbc.2012.15.4.373","volume":"15","author":"V Srivastava","year":"2012","unstructured":"Srivastava V, Basu S, Shukla VK. Seroma formation after breast cancer surgery: what we have learned in the last two decades. J Breast Cancer. 2012;15(4):373\u201380.","journal-title":"J Breast Cancer"},{"key":"7840_CR5","first-page":"CD006823","volume":"10","author":"DR Thomson","year":"2013","unstructured":"Thomson DR, Sadideen H, Furniss D. Wound drainage after axillary dissection for carcinoma of the breast. Cochrane Database Syst Rev. 2013;10:CD006823.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"7840_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.clbc.2016.12.013","volume":"17","author":"A Conversano","year":"2017","unstructured":"Conversano A, Mazouni C, Thomin A, Gaudin A, Fournier M, Rimareix F, et al. Use of low-thrombin fibrin sealant glue after axillary lymphadenectomy for breast cancer to reduce hospital length and seroma. Clin Breast Cancer. 2017;17(4):293\u20137.","journal-title":"Clin Breast Cancer"},{"issue":"13","key":"7840_CR7","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.1245\/s10434-020-08747-5","volume":"27","author":"YT Chang","year":"2020","unstructured":"Chang YT, Shih SL, Loh EW, Tam KW. Effects of fibrin sealant on seroma reduction for patients with breast cancer undergoing axillary dissection: meta-analysis of randomized controlled trials. Ann Surg Oncol. 2020;27(13):5286\u201395.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"7840_CR8","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1245\/s10434-016-5398-6","volume":"23","author":"J Gunn","year":"2016","unstructured":"Gunn J, Gibson T, Li Z, Diehl N, Bagaria S, McLaughlin S. Symptomatic axillary seroma after sentinel lymph node biopsy: incidence and treatment. Ann Surg Oncol. 2016;23(10):3347\u201353.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7840_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/bjs.4435","volume":"91","author":"PK Jain","year":"2004","unstructured":"Jain PK, Sowdi R, Anderson AD, MacFie J. Randomized clinical trial investigating the use of drains and fibrin sealant following surgery for breast cancer. Br J Surg. 2004;91(1):54\u201360.","journal-title":"Br J Surg"},{"issue":"8","key":"7840_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.clbc.2017.04.004","volume":"17","author":"K Vasileiadou","year":"2017","unstructured":"Vasileiadou K, Kosmidis C, Anthimidis G, Miliaras S, Kostopoulos I, Fahantidis E. Cyanoacrylate adhesive reduces seroma production after modified radical mastectomy or quadrantectomy with lymph node dissection-a prospective randomized clinical trial. Clin Breast Cancer. 2017;17(8):595\u2013600.","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"7840_CR11","doi-asserted-by":"publisher","first-page":"E136","DOI":"10.1055\/a-1216-0861","volume":"53","author":"D Ramos","year":"2021","unstructured":"Ramos D, Vazquez-Sequeiros E, Abadia P, Pina JD, Moreno I, Die Trill J, et al. Endoscopic management of acute anastomotic leakage after low colorectal anastomosis with cyanoacrylate bioglue (Glubran 2). Endoscopy. 2021;53(4):E136\u20137.","journal-title":"Endoscopy"},{"issue":"9","key":"7840_CR12","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","volume":"27","author":"G Hernandez","year":"2018","unstructured":"Hernandez G, Garin O, Pardo Y, Vilagut G, Pont A, Suarez M, et al. Validity of the EQ-5D-5L and reference norms for the Spanish population. Qual Life Res. 2018;27(9):2337\u201348.","journal-title":"Qual Life Res"},{"issue":"1","key":"7840_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13027-021-00358-3","volume":"16","author":"R Patrone","year":"2021","unstructured":"Patrone R, Granata V, Belli A, Palaia R, Albino V, Piccirillo M, et al. The safety and efficacy of Glubran 2 as biliostatic agent in liver resection. Infect Agent Cancer. 2021;16(1):19.","journal-title":"Infect Agent Cancer"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07840-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07840-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07840-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T10:10:43Z","timestamp":1708596643000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07840-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7840"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07840-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2467802\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the coordinating center (Health Consortium Maresme, Matar\u00f3 Hospital) on February 2022, code CEIm 11\/22. The trial is registered at ClinicalTrials.gov registry (NCT NCT05280353).The trial is also registered in NEOPs (investigacions cl\u00ednicas con productos sanitarios con marcado CE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Informed consent materials will be available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"142"}}